Targeted depletion of TRBV9⁺ T cells as immunotherapy in a patient with ankylosing spondylitis.

ABSTRACT: Autoimmunity is intrinsically driven by memory T and B cell clones inappropriately targeted at self-antigens. Selective depletion or suppression of self-reactive T cells remains a holy grail of autoimmune therapy, but disease-associated T cell receptors (TCRs) and cognate antigenic epitopes remained elusive. A TRBV9-containing CD8⁺ TCR motif was recently associated with the pathogenesis of ankylosing spondylitis, psoriatic arthritis and acute anterior uveitis, and cognate HLA-B*27-presented epitopes were identified. Following successful testing in nonhuman primate models, here we report human TRBV9⁺ T cell elimination in ankylosing spondylitis. The patient achieved remission within 3 months and ceased anti-TNF therapy after 5 years of continuous use. Complete remissio

SUBMITTER: Britanova OV 

PROVIDER: S-EPMC10667094 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature